Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) vs ADT only: Time to progression
Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) probably leads to lower time to progression (absolute effect size estimates based on… compared with ADT only (moderate certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) vs ADT only Time to progression (absolute effect size estimates based on progression rate at 5 years) Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) probably leads to lower time to progression (absolute effect size estimates based on… compared with ADT only (moderate certainty). Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer (2018) · Cochrane Headline outcomes only | HR 0.63 [0.56, 0.71] | 3 studies · 2261 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer 2018 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.